While the metabolic benefits of GLP-1 medicines, such as improved glucose control and weight loss, improve health and likely help reduce metabolic disease–associated complications, a growing body of evidence suggests that GLP-1 has intrinsic antiinflammatory actions that are independent of its metabolic actions. The gene discussed is GLP1R; the disease is metabolic disease.